ArtsAutosBooksBusinessEducationEntertainmentFamilyFashionFoodGamesGenderHealthHolidaysHomeHubPagesPersonal FinancePetsPoliticsReligionSportsTechnologyTravel

Qnexa, Contrave, and Lorcaserin - Three New Diet Pills seeking FDA approval

Updated on January 29, 2014
Photo courtesy of
Photo courtesy of


I found out about these three new potential diet pills Qnexa, Lorcaserin and Contrave when I was carrying out the research for my hub Hemopressin - A natural way to curb appetite? These three drugs are currently seeking FDA approval this year and it is causing something of a stir.

So why the stir?

You might well be asking why this is as we all know that FDA approval is needed before any drug can be marketed. Well the reason is two-fold. Firstly these three drugs are the first diet pills to seek FDA approval in a decade and secondly if approved these drugs stand to make millions of US dollars for the companies and their shareholders. The market for the treatment of obesity is huge and pharmaceutical companies from around the globe are all seeking the alchemy formula that will turn the base chemicals into gold! One estimate I’ve seen puts the global diet pill market at over $10 billion(US) by 2018. The News Update Video to the side provides details of a deal struck by one of the developers of the three drugs and the sums involved are not insignificant.

Photo courtesy of Janine on Flickr
Photo courtesy of Janine on Flickr

California Connection


What is also surprising is that the three companies each seeking approval for their drug Vivus Inc (Qnexa), Orexigen Therapeutics Inc (Contrave) and Arena Pharmaceuticals Inc (Lorcaserin) are all US companies and they are all based in California.  Vivus is based in Mountain View and Orexigen and Arena are both based in San Diego and none are what you would consider to be amongst the bigger players in the industry.

So what exactly will the FDA do

 The FDA will make a balanced judgement on the suitability of each drug in a number of key areas.

  1. Is the drug effective and safe?  They will weigh the drugs ability in providing weight loss against the side effects it may produce.

  2. Are the methods that will be used in manufacturing the drug and the controls that will be in place sufficient to ensure the drug's strength, quality, and purity?

  3. Is the drug's proposed labeling appropriate, and does it contain the necessary information?


Side Effects

We have all heard about the side effects of drugs and those readers, who are old enough to remember the horrendous problems of the diet pill Phen-Fen, will know that diet drugs can produce very serious side effects. Phen-Fen was taken off the market in October 1997 because of the serious and sometimes fatal damage it caused to heart values.

Whilst I would not expect any sympathy for the companies involved the side effects can cause serious financial damage to the pharmaceutical company. Wyeth has advised that it has set aside $21.1 billion (US) to cover the cost of the lawsuits arising from the damages caused by Phen-Fen.


Qnexa is a once-a-day, orally taken drug which provides a controlled release of two existing approved drugs phentermine and topiramate. Phentermine is a widely prescribed appetite surpressant and was the Phen in Phen-Fen and topiramite is an anticonvulsant drug. The combination of these two drugs in low doses to reduce the severity of the side effects has produced some very impressive weight loss in patients on the trial. Those who took Qnexa lost almost 9% more weight than those taking the placebo sugar pill so it comfortably meets the 5% measure that the FDA recommends for medical weight loss products.  The news video to the side gives details of two successful patients losing weight using Xnexa.

High doses of topiramate are known to cause birth defects in animals and those patients in the trial who were taking high doses of Qnexa reported three times as much anxiety and depression as the control group and also reported problems with memory, concentration and speech. Qnexa also appears to increase heart rate.


Like Qnexa Contrave is a combination of two existing approved drugs. Naltrexone which is used to treat addictions and Bupropion which is used to treat depression. In the trials Contrave also easily met the FDA 5% measure with patients typically losing between 9% and 15% of their body weight.

So far the only side effects I’ve seen reported are for nausea, headaches and constipation so the side effects do seem to be less serious than those for Qnexa.


Lorcaserin is a totally new drug but it has a similar chemical make up to Fenfluramine, the notorious Fen in Phen-fen. However in trials no heart value problems have been reported and it appears that of the three drugs it is the one with the least side effects. It is unfortunately ist is the least effective at producing weight loss although it does still meet that FDA 5% measure.

The side effects reported are headaches, nausea, dizziness, fatigue and a driness in the mouth and as it does not provide a feeling of elation it has a lower probability of producing addiction and abuse.


    0 of 8192 characters used
    Post Comment

    • Amber Allen profile imageAUTHOR

      Amber Allen 

      8 years ago

      Hi Pamela

      Thanks for commenting on my hub. Unfortunately all drugs have side effects to one degree or another.


    • Pamela99 profile image

      Pamela Oglesby 

      8 years ago from Sunny Florida

      Amber, This is an interesting article as I heard this drug mentioned on TV and was wondering if it had side effects like so many do. Good article.


    This website uses cookies

    As a user in the EEA, your approval is needed on a few things. To provide a better website experience, uses cookies (and other similar technologies) and may collect, process, and share personal data. Please choose which areas of our service you consent to our doing so.

    For more information on managing or withdrawing consents and how we handle data, visit our Privacy Policy at:

    Show Details
    HubPages Device IDThis is used to identify particular browsers or devices when the access the service, and is used for security reasons.
    LoginThis is necessary to sign in to the HubPages Service.
    Google RecaptchaThis is used to prevent bots and spam. (Privacy Policy)
    AkismetThis is used to detect comment spam. (Privacy Policy)
    HubPages Google AnalyticsThis is used to provide data on traffic to our website, all personally identifyable data is anonymized. (Privacy Policy)
    HubPages Traffic PixelThis is used to collect data on traffic to articles and other pages on our site. Unless you are signed in to a HubPages account, all personally identifiable information is anonymized.
    Amazon Web ServicesThis is a cloud services platform that we used to host our service. (Privacy Policy)
    CloudflareThis is a cloud CDN service that we use to efficiently deliver files required for our service to operate such as javascript, cascading style sheets, images, and videos. (Privacy Policy)
    Google Hosted LibrariesJavascript software libraries such as jQuery are loaded at endpoints on the or domains, for performance and efficiency reasons. (Privacy Policy)
    Google Custom SearchThis is feature allows you to search the site. (Privacy Policy)
    Google MapsSome articles have Google Maps embedded in them. (Privacy Policy)
    Google ChartsThis is used to display charts and graphs on articles and the author center. (Privacy Policy)
    Google AdSense Host APIThis service allows you to sign up for or associate a Google AdSense account with HubPages, so that you can earn money from ads on your articles. No data is shared unless you engage with this feature. (Privacy Policy)
    Google YouTubeSome articles have YouTube videos embedded in them. (Privacy Policy)
    VimeoSome articles have Vimeo videos embedded in them. (Privacy Policy)
    PaypalThis is used for a registered author who enrolls in the HubPages Earnings program and requests to be paid via PayPal. No data is shared with Paypal unless you engage with this feature. (Privacy Policy)
    Facebook LoginYou can use this to streamline signing up for, or signing in to your Hubpages account. No data is shared with Facebook unless you engage with this feature. (Privacy Policy)
    MavenThis supports the Maven widget and search functionality. (Privacy Policy)
    Google AdSenseThis is an ad network. (Privacy Policy)
    Google DoubleClickGoogle provides ad serving technology and runs an ad network. (Privacy Policy)
    Index ExchangeThis is an ad network. (Privacy Policy)
    SovrnThis is an ad network. (Privacy Policy)
    Facebook AdsThis is an ad network. (Privacy Policy)
    Amazon Unified Ad MarketplaceThis is an ad network. (Privacy Policy)
    AppNexusThis is an ad network. (Privacy Policy)
    OpenxThis is an ad network. (Privacy Policy)
    Rubicon ProjectThis is an ad network. (Privacy Policy)
    TripleLiftThis is an ad network. (Privacy Policy)
    Say MediaWe partner with Say Media to deliver ad campaigns on our sites. (Privacy Policy)
    Remarketing PixelsWe may use remarketing pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to advertise the HubPages Service to people that have visited our sites.
    Conversion Tracking PixelsWe may use conversion tracking pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to identify when an advertisement has successfully resulted in the desired action, such as signing up for the HubPages Service or publishing an article on the HubPages Service.
    Author Google AnalyticsThis is used to provide traffic data and reports to the authors of articles on the HubPages Service. (Privacy Policy)
    ComscoreComScore is a media measurement and analytics company providing marketing data and analytics to enterprises, media and advertising agencies, and publishers. Non-consent will result in ComScore only processing obfuscated personal data. (Privacy Policy)
    Amazon Tracking PixelSome articles display amazon products as part of the Amazon Affiliate program, this pixel provides traffic statistics for those products (Privacy Policy)